FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3202181822> ?p ?o ?g. }

• W3202181822 abstract "Abstract Background Clinical management of skin-toxicity associated with the use of anti-Epidermal Growth Factor Receptor (EGFR) antibodies to treat colorectal cancer maintains quality of life of patients with colorectal cancer. Results of clinical trials have recommended the efficacy of prophylactic treatment, but the cost-effectiveness is unclear. This study examined the cost-effectiveness of preventive skin care for skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer from the perspective of the Japanese healthcare payer. Methods The data source was J-STEPP trial, which compared preemptive skin treatment with reactive treatment in third-line panitumumab therapy for KRAS wild type metastatic colorectal cancer in Japan. The costs and effectiveness of preemptive treatment was compared with reactive treatment in a 3-year time horizon using a 4-state partitioned survival analysis. The health outcome was quality-adjusted life-years (QALYs). The costs were 2020 revisions to the drug prices. The robustness of the model was verified by one-way sensitivity analysis and a probabilistic sensitivity analysis (PSA). A 2% annual discount was applied to the expenses and QALYs. Willingness-to-pay (WTP) threshold of 5 million JPY was used. Results Preemptive treatment had incremental effects of 0.0029 QALYs, incremental costs of 5300 JPY (48.6 USD), and incremental cost-effectiveness ratios (ICER) of 1,843,395 JPY (16,912 USD) per QALY. The variability of preemptive and reactive treatment costs for skin-toxicity and the disutility of skin-toxicity had a large impact on ICER. From PSA, the cost-effectiveness rate of preemptive treatment was 75.0%. Conclusions The cost to effectiveness of preemptive treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type mCRC is not high." @default.
• W3202181822 created "2021-10-11" @default.
• W3202181822 creator A5075462361 @default.
• W3202181822 creator A5080991905 @default.
• W3202181822 date "2021-10-01" @default.
• W3202181822 modified "2023-10-15" @default.
• W3202181822 title "Cost-effectiveness of preemptive skin treatment to prevent skin-toxicity caused by panitumumab in third-line therapy for KRAS wild type metastatic colorectal cancer in Japan" @default.
• W3202181822 cites W1992280558 @default.
• W3202181822 cites W2005348280 @default.
• W3202181822 cites W2028045370 @default.
• W3202181822 cites W2109643669 @default.
• W3202181822 cites W2120458151 @default.
• W3202181822 cites W2126499930 @default.
• W3202181822 cites W2128473443 @default.
• W3202181822 cites W2160344439 @default.
• W3202181822 cites W2161016520 @default.
• W3202181822 cites W2296800272 @default.
• W3202181822 cites W2504049772 @default.
• W3202181822 cites W2529553496 @default.
• W3202181822 cites W2792837005 @default.
• W3202181822 cites W2889646458 @default.
• W3202181822 cites W2891113517 @default.
• W3202181822 cites W2966407525 @default.
• W3202181822 cites W2998897134 @default.
• W3202181822 cites W4211133582 @default.
• W3202181822 doi "https://doi.org/10.1186/s40780-021-00218-7" @default.
• W3202181822 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8485424" @default.
• W3202181822 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34593037" @default.
• W3202181822 hasPublicationYear "2021" @default.
• W3202181822 type Work @default.
• W3202181822 sameAs 3202181822 @default.
• W3202181822 citedByCount "1" @default.
• W3202181822 countsByYear W32021818222023 @default.
• W3202181822 crossrefType "journal-article" @default.
• W3202181822 hasAuthorship W3202181822A5075462361 @default.
• W3202181822 hasAuthorship W3202181822A5080991905 @default.
• W3202181822 hasBestOaLocation W32021818221 @default.
• W3202181822 hasConcept C121608353 @default.
• W3202181822 hasConcept C126322002 @default.
• W3202181822 hasConcept C143998085 @default.
• W3202181822 hasConcept C2778332735 @default.
• W3202181822 hasConcept C2781187634 @default.
• W3202181822 hasConcept C29730261 @default.
• W3202181822 hasConcept C526805850 @default.
• W3202181822 hasConcept C535046627 @default.
• W3202181822 hasConcept C71924100 @default.
• W3202181822 hasConceptScore W3202181822C121608353 @default.
• W3202181822 hasConceptScore W3202181822C126322002 @default.
• W3202181822 hasConceptScore W3202181822C143998085 @default.
• W3202181822 hasConceptScore W3202181822C2778332735 @default.
• W3202181822 hasConceptScore W3202181822C2781187634 @default.
• W3202181822 hasConceptScore W3202181822C29730261 @default.
• W3202181822 hasConceptScore W3202181822C526805850 @default.
• W3202181822 hasConceptScore W3202181822C535046627 @default.
• W3202181822 hasConceptScore W3202181822C71924100 @default.
• W3202181822 hasIssue "1" @default.
• W3202181822 hasLocation W32021818221 @default.
• W3202181822 hasLocation W32021818222 @default.
• W3202181822 hasLocation W32021818223 @default.
• W3202181822 hasOpenAccess W3202181822 @default.
• W3202181822 hasPrimaryLocation W32021818221 @default.
• W3202181822 hasRelatedWork W1541436518 @default.
• W3202181822 hasRelatedWork W1980946342 @default.
• W3202181822 hasRelatedWork W1997977112 @default.
• W3202181822 hasRelatedWork W2034550393 @default.
• W3202181822 hasRelatedWork W2524774903 @default.
• W3202181822 hasRelatedWork W2589642515 @default.
• W3202181822 hasRelatedWork W2617055067 @default.
• W3202181822 hasRelatedWork W3000288349 @default.
• W3202181822 hasRelatedWork W3094547569 @default.
• W3202181822 hasRelatedWork W3180628252 @default.
• W3202181822 hasVolume "7" @default.
• W3202181822 isParatext "false" @default.
• W3202181822 isRetracted "false" @default.
• W3202181822 magId "3202181822" @default.
• W3202181822 workType "article" @default.